Testing Tris-CAR-T cell therapy for newly diagnosed glioblastoma
Official title: Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study tests a new cell therapy, given along with standard treatment, for people just diagnosed with glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary.
Read our full plain-language summary
What the trial team says
This is an investigator-initiated, randomized, open-label, parallel-controlled clinical study designed to evaluate the efficacy and safety of locally administered Tris-CAR-T cells in adults with newly diagnosed glioblastoma. A total of 60 postoperative participants with IDH-wildtype WHO CNS grade 4 glioblastoma will be randomized 1:1 to the experimental group or the control group, with 30 participants in each group. Participants in the experimental group will receive Ommaya reservoir implantation followed by local intratumoral or intraventricular Tris-CAR-T cell injections, and then standard temozolomide-based chemoradiotherapy and adjuvant temozolomide. If tumor progression occurs during Tris-CAR-T cell therapy, Tris-CAR-T treatment will be discontinued, and participants will transition to standard temozolomide-based chemoradiotherapy. Participants in the control group will receive standard temozolomide-based chemoradiotherapy and adjuvant temozolomide. The primary objective is to evaluate progression-free survival. Secondary objectives include overall survival, 12-month objective response rate, 12-month disease control rate, and safety.
Key facts
- Registry number
- NCT07873996
- Stage of testing
- Phase 2/Phase 3
- Conditions studied
- Newly Diagnosed Glioblastoma, IDH-wildtype
Where it is running
This trial lists 1 site.
-
Beijing Municipality
- Beijing Tiantan Hospital, Capital Medical University (Beijing)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.